文献速递头痛与眩晕

枕神经刺激预防药物难治性慢性丛集性头痛的3期试验

Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial.
PubMed 文献 · Lancet Neurol · 2021-01-01

ICON是一项国际多中心随机双盲3期电剂量对照试验,纳入药物难治性慢性丛集性头痛(MICCH)患者,比较100%与30%强度枕神经刺激(ONS)24周的疗效。两种强度均安全且耐受良好。

要点

  • 100%与30%强度ONS在双盲期结束时发作频率组间差异无统计学意义(95%CI跨0)。
  • 常见不良事件为局部疼痛、伤口愈合不良、颈部僵硬和硬件损坏,均为已知类型。

核心结论

  • 在药物难治性慢性丛集性头痛患者中,100%和30%两种强度的ONS均能大幅降低发作频率,且安全、耐受良好。

研究设计与样本

  • 研究者发起的国际多中心随机双盲3期电剂量对照试验,在荷兰4家、比利时1家、德国1家、匈牙利1家医院开展。
  • 经12周基线观察后,将符合MICCH、每周至少4次发作、对至少3种标准预防药无反应的患者按1:1随机分配至100%或30%强度ONS,双盲期24周,第25-48周为个体化开放标签ONS。
  • 共入组150例,随机分配131例(87%):100%组65例(50%),30%组66例(50%);30%组中1例未植入,被排除在意向性治疗分析之外。

主要发现

  • 双盲期100%ONS组发生129例不良事件、30%ONS组95例;严重不良事件分别为17例和8例,均因轻微硬件相关问题需短暂住院,无意外不良事件。

关键数值与推荐

  • 入组条件:MICCH、每周至少4次发作、对至少3种标准预防药物无反应。
  • 主要结局:第21-24周每周平均发作频率与基线的比较,以及组间差异。
  • 因基线发作频率呈偏态分布,采用对数转换分析并以中位数呈现结果。

临床怎么用

  • 对于至少3种标准预防药物无效的MICCH患者,ONS可作为减少发作频率的治疗选择之一。
  • 100%与30%强度在双盲期内的疗效差异未达统计学显著,提示刺激强度与疗效的关系尚需进一步研究。
  • 需关注局部疼痛、伤口愈合不良、颈部僵硬和硬件损坏等不良事件,严重者多需短暂住院处理。

局限性

  • 30%ONS组有1例未植入并被排除在意向性治疗分析之外。
  • 基线发作频率呈偏态分布,数据分析采用对数转换和中位数呈现。
  • 因ONS产生感觉异常,无法与安慰剂对照,只能采用高强度和低强度电剂量对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Occipital nerve stimulation (ONS) has shown promising results in small uncontrolled trials in patients with medically intractable chronic cluster headache (MICCH). We aimed to establish whether ONS could serve as an effective treatment for patients with MICCH. METHODS: The ONS in MICCH (ICON) study is an investigator-initiated, international, multicentre, randomised, double-blind, phase 3, electrical dose-controlled clinical trial. The study took place at four hospitals in the Netherlands, one hospital in Belgium, one in Germany, and one in Hungary. After 12 weeks' baseline observation, patients with MICCH, at least four attacks per week, and history of being non-responsive to at least three standard preventive drugs, were randomly allocated (at a 1:1 ratio using a computer-generated permuted block) to 24 weeks of occipital nerve stimulation at either 100% or 30% of the individually determined range between paraesthesia threshold and near-discomfort (double-blind study phase). Because ONS causes paraesthesia, preventing masked comparison versus placebo, we compared high-intensity versus low-intensity ONS, which are hypothesised to cause similar paraesthesia, but with different efficacy. In weeks 25-48, participants received individually optimised open-label ONS. The primary outcome was the weekly mean attack frequency in weeks 21-24 compared with baseline across all patients and, if a decrease was shown, to show a group-wise difference. The trial is closed to recruitment (ClinicalTrials.gov NCT01151631). FINDINGS: Patients were enrolled between Oct 12, 2010, and Dec 3, 2017. We enrolled 150 patients and randomly assigned 131 (87%) to treatment; 65 (50%) patients to 100% ONS and 66 (50%) to 30% ONS. One of the 66 patients assigned to 30% ONS was not implanted and was therefore excluded from the intention-to-treat analysis. Because the weekly mean attack frequencies at baseline were skewed (median 15·75; IQR 9·44 to 24·75) we used log transformation to analyse the data and medians to present the results. Median weekly mean attack frequencies in the total population decreased from baseline to 7·38 (2·50 to 18·50; p<0·0001) in weeks 21-24, a median change of -5·21 (-11·18 to -0·19; p<0·0001) attacks per week. In the 100% ONS stimulation group, mean attack frequency decreased from 17·58 (9·83 to 29·33) at baseline to 9·50 (3·00 to 21·25) at 21-24 weeks (median change from baseline -4·08, -11·92 to -0·25), and for the 30% ONS stimulation group, mean attack frequency decreased from 15·00 (9·25 to 22·33) to 6·75 (1·50 to 16·50; -6·50, -10·83 to -0·08). The difference in median weekly mean attack frequency between groups at the end of the masked phase in weeks 21-24 was -2·42 (95% CI -5·17 to 3·33). In the masked study phase, 129 adverse events occurred with 100% ONS and 95 occurred with 30% ONS. None of the adverse events was unexpected but 17 with 100% ONS and eight with 30% ONS were labelled as serious, given they required brief hospital admission for minor hardware-related issues. The most common adverse events were local pain, impaired wound healing, neck stiffness, and hardware damage. INTERPRETATION: In patients with MICCH, both 100% ONS intensity and 30% ONS intensity substantially reduced attack frequency and were safe and well tolerated. Future research should focus on optimising stimulation protocols and disentangling the underlying mechanism of action. FUNDING: The Netherlands Organisation for Scientific Research, the Dutch Ministry of Health, the NutsOhra Foundation from the Dutch Health Insurance Companies, and Medtronic.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Wilbrink LA, de Coo IF, Doesborg PGG, et al. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurol. 2021. PMID: 34146510. doi:10.1016/S1474-4422(21)00101-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。